Peptilogics

Peptilogics, Inc. is a biotechnology company based in West Mifflin, Pennsylvania, that focuses on developing novel peptide therapeutics to combat multidrug-resistant bacterial infections. Established in 2013, Peptilogics employs a unique computational platform that facilitates drug discovery by exploring new chemical design spaces and ensuring the biological viability and manufacturability of potential therapeutics. The company's lead candidate, PLG0206, is a broad-spectrum anti-infective peptide that has received FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation, targeting prosthetic joint infections, which represent a significant unmet medical need. Peptilogics aims to provide effective solutions to address the challenges posed by resistant bacteria and biofilms, ultimately improving treatment outcomes for patients.